


## **Single Technology Appraisal**

# Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]

### **Final Stakeholder List**

Dec 1sts and Occasión	Description of the second of t
Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	Submit of appeal)
Company	General
<ul><li>Ipsen (cabozantinib)</li></ul>	All Wales Therapeutics and Toxicology
	Centre
Patient/carer groups	Allied Health Professionals Federation
Black Health Agency for Equality	Board of Community Health Councils in
Bowel Cancer UK	Wales
Cancer Black Care	British National Formulary
Cancer52	Care Quality Commission
Gist Cancer UK	Department of Health, Social Services
Guts UK	and Public Safety for Northern Ireland
Helen Rollason Cancer Charity	Healthcare Improvement Scotland
<ul> <li>Independent Cancer Patients Voice</li> </ul>	<ul> <li>Medicines and Healthcare products</li> </ul>
<ul> <li>Insulinoma Support Network</li> </ul>	Regulatory Agency
Macmillan Cancer Support	National Association of Primary Care
Maggie's Centres	National Pharmacy Association
Marie Curie	NHS Confederation
Neuroendocrine Cancer UK	Scottish Medicines Consortium
OG Support	Scottish Society of Gastroenterology
Pancreatic Cancer Action	Welsh Government
Pancreatic Cancer UK	Welsh Health Specialised Services     Committee
South Asian Health Foundation	Committee
Specialised Healthcare Alliance	Comparator companies
Tenovus Cancer Care	Accord Healthcare (5-fluorouracil,
Hooltheare professional groups	temozolomide)
<ul><li>Healthcare professional groups</li><li>Association of Cancer Physicians</li></ul>	Amarox (capecitabine)
<ul> <li>British Geriatrics Society</li> </ul>	Baxter (doxorubicin)
British Nuclear Medicine Society	Dr Reddy's Laboratories (capecitabine,
British Oncology Pharmacy	everolimus, sunitinib)
Association	Esteve Pharmaceuticals (streptozocin)
British Psychosocial Oncology	Ethypharm UK (everolimus)
Society	Glenmark Pharmaceuticals
British Society of Gastroenterology	(capecitabine)
Cancer Research UK	Hospira UK (carboplatin, cisplatin, 5-
Royal College of General	fluorouracil)
Practitioners	medac GmBH (doxorubicin, 5-
Royal College of Nursing	fluorouracil,)

Stakeholder list for the evaluation of cabozantinib for treating advanced pancreatic tumours that have progressed after systemic treatment [ID6474]



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society for Endocrinology</li> <li>UK Acute Oncology Society</li> <li>UK Clinical Pharmacy Association</li> <li>UKI NETS</li> <li>UK Oncology Nursing Society</li> </ul> Others <ul> <li>Department of Health and Social Care</li> <li>NHS England</li> </ul>	<ul> <li>Merck Sharp &amp; Dohme (temozolomide)</li> <li>MSN Laboratories (sunitinib)</li> <li>Mylan (sunitinib)</li> <li>Neon Healthcare (etoposide</li> <li>Novartis (everolimus, lutetium (177Lu) oxodotreotide)</li> <li>Pfizer (doxorubicin, sunitinib)</li> <li>Piramal Critical Care (sunitinib)</li> <li>Sandoz (cisplatin, everolimus, sunitinib)</li> <li>Seacross (doxorubicin)</li> <li>Sun Pharma (temozolomide)</li> <li>Teva Pharma (sunitinib)</li> <li>Zentiva (sunitinib)</li> <li>Relevant research groups</li> <li>Cochrane Gut</li> <li>Cochrane Metabolic &amp; Endocrine Disorders Group</li> <li>Genomics England</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> <li>Associated Public Health groups</li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient

Stakeholder list for the evaluation of cabozantinib for treating advanced pancreatic tumours that have progressed after systemic treatment [ID6474]

Issue date: February 2025



organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### **Commentators**

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.